A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Recruiting
Observational Study
Psoriasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,500 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Have been diagnosed with plaque psoriasis by a dermatologist
* Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
* Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the…
Contacts
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
CONTACT
First line of the email MUST contain the NCT# and Site #.
CONTACT